Psychemedics Stock Forecast, Price & News

Psychemedics (NASDAQ:PMD) Frequently Asked Questions

How has Psychemedics' stock price been impacted by Coronavirus?

Psychemedics' stock was trading at $6.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PMD shares have increased by 1.4% and is now trading at $7.05.
View which stocks have been most impacted by COVID-19.

Are investors shorting Psychemedics?

Psychemedics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 18,700 shares, a drop of 30.5% from the October 31st total of 26,900 shares. Based on an average daily volume of 21,800 shares, the short-interest ratio is currently 0.9 days. Currently, 0.4% of the shares of the stock are short sold.
View Psychemedics' Short Interest.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Psychemedics.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) announced its quarterly earnings data on Tuesday, April, 23rd. The company reported $0.11 earnings per share (EPS) for the quarter. The company earned $9.82 million during the quarter. Psychemedics had a negative net margin of 6.42% and a negative trailing twelve-month return on equity of 11.16%.
View Psychemedics' earnings history.

Who are Psychemedics' key executives?

Psychemedics' management team includes the following people:

• Raymond C. Kubacki, Chairman, President & Chief Executive Officer
• Charles M. Doucot, Executive Vice President
• Sarah E. Ashby, Vice President & General Counsel
• Andrew Limbek, Vice President & Controller
• Michael I. Schaffer, Vice President-Laboratory Operations

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics CEO Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among Psychemedics' employees.

Who are some of Psychemedics' key competitors?

Some companies that are related to Psychemedics include Exagen (XGN), Biocept (BIOC), OpGen (OPGN), Vyant Bio (VYNT), CannLabs (CANL), PharmChem (PCHM), AnPac Bio-Medical Science (ANPC), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), Zicix (ZICX), First Choice Healthcare Solutions (FCHS), PotNetwork (POTN), ACI Global (ACGJ), Aeon Global Health (AGHC) and CBA Florida (CBAI).
View all of PMD's competitors.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.74%), Crawford Investment Counsel Inc. (5.07%), Dimensional Fund Advisors LP (1.37%), Tieton Capital Management LLC (1.07%), Geode Capital Management LLC (0.62%) and Moors & Cabot Inc. (0.54%). Company insiders that own Psychemedics stock include Fred J Weinert, Michael I Schaffer and Raymond C Kubacki Jr.
View institutional ownership trends for Psychemedics.

Which institutional investors are selling Psychemedics stock?

PMD stock was sold by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, and Crawford Investment Counsel Inc..
View insider buying and selling activity for Psychemedics or view top insider-selling stocks.

Which institutional investors are buying Psychemedics stock?

PMD stock was acquired by a variety of institutional investors in the last quarter, including Moors & Cabot Inc., HighMark Wealth Management LLC, and Geode Capital Management LLC. Company insiders that have bought Psychemedics stock in the last two years include Fred J Weinert, Michael I Schaffer, and Raymond C Kubacki Jr.
View insider buying and selling activity for Psychemedics or or view top insider-buying stocks.

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $7.05.

How much money does Psychemedics make?

Psychemedics has a market capitalization of $39.07 million and generates $21.36 million in revenue each year. The company earns $-3.86 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does Psychemedics have?

Psychemedics employs 138 workers across the globe.

When was Psychemedics founded?

Psychemedics was founded in 1985.

What is Psychemedics' official website?

The official website for Psychemedics is www.psychemedics.com.

Where are Psychemedics' headquarters?

Psychemedics is headquartered at 289 GREAT ROAD Suite 200, ACTON MA, 01720.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The company can be reached via phone at (978) 206-8220 or via fax at 978-264-9236.